

Table S1. Univariate regression analysis - Cox regression model for CDK4/6i dose reduction.

Variable		HR	95 CI	P value
Age	<50 (ref) vs. ≥50	0.63	0.33-1.22	0.17
ECOG	0 (ref) vs. 1	2.22	1.07-4.61	0.03
	0 (ref) vs. 2	1.08	0.37-3.10	0.89
Disease	De novo (ref) vs. Recurrent	1.13	0.58-2.20	0.71
Previous CHT	Yes (ref) vs. No	1.21	0.64-2.29	0.56
Line of treatment	First (ref) vs. Second	0.93	0.46-1.89	0.85
CDK4/6i	Rib (ref) vs. Palb	1.06	0.53-2.11	0.88
	Rib (ref) vs. Abem	0.39	0.05-2.88	0.36
RT	Concurrent (ref) vs. Sequential	0.60	0.32-1.15	0.13
RT area	Bone (ref) vs. Not-bone	1.63	0.84-3.17	0.15
Neutr in C1D14	G0 (ref) vs. G1-2	1.85	0.87-3.97	0.11
	G0 (ref) vs. G3-4	3.84	1.62-9.13	0.002
Neutr in C2D1	G0 (ref) vs. G1-2	2.29	0.65-8.07	0.20
	G0 (ref) vs. G3-4	16.11	4.73-54.92	< 0.001

Abbreviations: ref – reference; ECOG - Performance status assessed by Eastern Cooperative Oncology; CHT – chemotherapy; CDK4/6i - Cyclin-dependent kinase 4 and 6 inhibitors; RT – radiotherapy; Neutr – neutropenia; 0-no neutropenia; 1-neutropenia G1; 2-neutropenia G2; 3-neutropenia G3; 4-neutropenia G4; Rib – ribociclib; Palb – palbociclib; Abem – abemaciclib;

Table S2. Multivariate regression analysis - Cox regression model for CDK4/6i dose reduction. Variables with p ≤ 0.2 in the univariate regression analysis were chosen for this analysis.

Variable		HR	95 CI	P value
Age	<50 (ref) vs. ≥50	0.96	0.48-1.22	0.92
ECOG	0 (ref) vs. 1	3.13	1.37-7.12	0.007
	0 (ref) vs. 2	1.88	0.56-6.30	0.31
RT	Concurrent (ref) vs. Sequential	0.96	0.48-1.94	0.91
RT area	Bone (ref) vs. Not-bone	1.95	0.97-3.95	0.06
Neutr in C1D14	G0 (ref) vs. G1-2	0.38	0.14-1.00	0.05
	G0 (ref) vs. G3-4	1.14	0.40-3.29	0.81
Neutr in C2D1	G0 (ref) vs. G1-2	2.99	0.82-10.94	0.10
	G0 (ref) vs. G3-4	39.90	9.33-170.66	< 0.001

Abbreviations: ref – reference; ECOG - Performance status assessed by Eastern Cooperative Oncology; RT – radiotherapy; Neutr – neutropenia; 0-no neutropenia; 1-neutropenia G1; 2-neutropenia G2; 3-neutropenia G3; 4-neutropenia G4;